Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has experienced a noteworthy increase in short interest during December. As of December 31, the total short interest stood at 6,000,000 shares, marking a rise of 6.0% from the December 15 total of 5,660,000 shares. Given the average trading volume of 250,800 shares, the days-to-cover ratio sits at 23.9 days. This indicates that approximately 31.2% of the company's stock is currently sold short.

Hedge Funds' Positions in Dianthus Therapeutics

Recent actions from large investors show a shift in their positions regarding Dianthus Therapeutics. For instance, Quest Partners LLC made a significant move by increasing its stake in Dianthus Therapeutics by an astonishing 112,400.0% during the third quarter. After acquiring an additional 1,124 shares, Quest now holds 1,125 shares valued at $31,000. In a similar vein, SG Americas Securities LLC raised its holdings by 9.2% in the fourth quarter, now owning 9,653 shares worth $210,000 after acquiring 814 additional shares. Furthermore, The Manufacturers Life Insurance Company invested in a new stake valued at around $236,000 during the second quarter. Additionally, Fred Alger Management LLC elevated its stake by 52.5% in the third quarter and now holds 9,633 shares worth approximately $264,000 after purchasing another 3,316 shares. Lastly, Point72 DIFC Ltd also acquired a new position during the second quarter, valued at about $334,000. Currently, hedge funds and other institutional investors own approximately 47.53% of the stock.

Insights from Wall Street Analysts

Dianthus Therapeutics has attracted the attention of several analysts recently. On December 20, TD Cowen initiated coverage of DNTH, providing a "buy" rating for the company. Oppenheimer raised its target price from $48.00 to $52.00 and assigned a rating of "outperform" on November 11. Additionally, Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating on December 12. HC Wainwright also reiterated a "buy" rating, setting a price target of $40.00 on the same day. Overall, the stock has received eight buy ratings and two strong buy ratings from analysts, resulting in an average rating of "Buy" and an average price target of $46.43 according to MarketBeat.com.

Dianthus Therapeutics Stock Updates

In recent trading, DNTH stock rose by 4.1%, reaching $20.00. On that day, trading volume hit 156,254 shares, in contrast to its average volume of 199,749. The company boasts a market capitalization of $592 million, along with a negative PE ratio of -8.00 and a beta of 1.74. Its 50-day moving average is $23.62, while its 200-day moving average stands at $26.40. Over the past year, the stock has experienced a low of $10.65 and a high of $33.77.

Dianthus Therapeutics most recently announced quarterly earnings on November 7, reporting earnings per share (EPS) of -$0.74, which fell short of analysts' consensus estimates of -$0.59 by a margin of $0.15. The company recorded a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Revenue for the quarter reached $2.17 million, significantly surpassing the consensus estimate of $1.07 million. Analysts predict an average EPS of -2.61 for the current year.

Company Overview of Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing complement therapeutics for severe autoimmune and inflammatory diseases. Among its key projects is DNTH103, a monoclonal antibody currently in Phase 2 clinical trials, aimed at treating conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

growth, investors, analysts